HEMATOPATHOLOGY DIAGNOSIS & SUBTYPING. Use of IHC. Use of Polymerase Chain Reaction (PCR) Use of Flow Cytometry
|
|
- Blaze Campbell
- 6 years ago
- Views:
Transcription
1 HEMATOPATHOLOGY DIAGNOSIS & SUBTYPING HEMATOPATHOLOGY DIAGNOSIS & SUBTYPING The 2008 WHO classification system for tumors of hematopoietic and lymphoid tissues specifies that various combinations of immunophenotypic studies (e.g., IHC and/or flow cytometry) and molecular studies (e.g., cytogenetics and/or fluorescence in situ hybridization [FISH] and/or PCR) are required for the diagnosis of virtually all lymphomas, leukemias, plasma cell neoplasms, and other less common hematolymphoid neoplasms. Use of IHC Classifying hematopoietic malignancies: As Table 1 (page 54) suggests, in addition to identifying mature and immature B and T cell neoplasms and Hodgkin lymphoma, IHC can identify virtually all other hematolymphoid malignancies, including NK cell neoplasms, precursor B- and T-lymphoblastic leukemia/ lymphoma, plasma cell neoplasms, myeloid leukemia/sarcoma, blastic plasmacytoid dendritic cell neoplasms, Langerhans cell histiocytosis, and mastocytosis. Helping establish certain benign diagnoses: A number of benign diseases can cause histologic changes that mimic hematolymphoid malignancies. IHC and related techniques can be very helpful in preventing the misdiagnosis of such diseases as neoplastic. For example, infectious mononucleosis (IM) can produce a highly atypical interfollicular hyperplasia in affected lymph node or tonsil that can mimic non-hodgkin or Hodgkin lymphoma. Special studies to detect Epstein-Barr virus (EBV)-infected cells (particularly EBER-1 in situ hybridization and occasionally EBV LMP IHC) are critical to making the diagnosis of IM in the appropriate clinical and serological setting (i.e., detection of an IgM antibody against the viral capsid antigen). Several years ago, PhenoPath made an important improvement to the reliability of our EBER-1 assay, by always performing it in parallel with in situ hybridization to detect the ubiquitous small nuclear U6 RNA. This serves as a positive internal control to document adequate mrna preservation in the tissue in order for the EBER-1 result to be interpretable. Other infections that can be documented by antibodies validated for clinical use at PhenoPath include: cytomegalovirus (CMV), herpes virus (HSV) I and II, varicella zoster (VZ), adenovirus, SV40/polyoma virus, toxoplasma, and chlamydia. HHV8 infection, which is often associated with malignancy, can also be documented by IHC at PhenoPath. A recently recognized, benign lymphoplasmacytic proliferation, IgG4-related sclerosing disease, can histologically mimic low-grade B cell lymphomas with plasmacytic differentiation. This process is almost always identified as benign by kappa/lambda immunostains demonstrating polytypic plasma cells, while the unique, IgG4-predominant nature of the plasma cells is demonstrated by showing a significantly increased proportion of IgG4-positive plasma cells among the total IgG-positive plasma cells. In tissues affected by IgG4-related sclerosing disease, this proportion is typically greater than 50%, while in unaffected tissues this proportion is typically 10% or less. Both IgG4 and generic IgG IHC are validated for clinical use at PhenoPath. Note that IgG4-related sclerosing disease is reported to be highly responsive to corticosteroid therapy. Use of Flow Cytometry Hematopoietic cell populations can be readily characterized by flow cytometric methods using antibodies to a large number of cell surface and intracellular antigens (see PhenoPath Science and Technology section of this guide). Flow cytometry allows for the rapid identification of immunophenotypic abnormalities associated with malignancy, including aberrant loss or gain of antigen expression, as well as monoclonality. Specifically, monoclonality can usually be established for B cells (light chain restriction), plasma cells (light chain restriction), alpha-beta T cells (restricted TCR-beta expression), and NK cells (restricted KIR expression). In addition, for both acute myeloid and lymphoid leukemias, the flow cytometric immunophenotype often gives strong clues to an underlying recurrent cytogenetic abnormality. Flow cytometric analysis is performed on fresh specimens including peripheral blood, bone marrow, body fluid, and tissues, and can be used to diagnose the full range of hematolymphoid neoplasms, plus a subset of non-hematopoietic tumors such as small cell carcinomas. PhenoPath utilizes state-of-the-art flow cytometers with three lasers and ten fluorescence detectors, providing 10-color flow cytometric evaluation. By determining the number of unique pairwise antigen comparisons possible with different flow cytometric methodologies (each pairwise antigen comparison is seen graphically as a dot-plot ), one can demonstrate that 10-color clinical flow cytometry provides 7.5 times the information of 4-color flow, 3 times the information of 6-color flow, and 61% more information than 8-color flow. The great efficiency of 10-color flow improves case turnaround time, and is of particular benefit when only a small amount of material is available or when minimal residual disease is being sought in the post-therapy setting. See Table 1 (page 54) for a list of antigens evaluated in the various PhenoPath flow cytometry panels. Importantly, in all cases the PhenoPath hematopathologist reviews a Wright-stained smear or cytocentrifuge preparation in parallel with the flow data, to confirm the flow findings are appropropriate. In many cases, the PhenoPath hematopathologist notifies the referring physician (by phone or ) at the time the diagnosis is finalized, to provide additional confirmation that the flow findings are concordant with the sample morphology at the referring institution. PhenoPath s flow cytometry reports include both a detailed comment describing the key findings leading to the interpretation, and flow cytometric histograms ( dot-plots ) showing the key data on which the diagnosis was based. These histograms enable easy identification of the neoplastic phenotype, for following the patient s disease in subsequent specimens. Situations in which 10-color flow cytometry is particularly useful include: Diagnosis and subclassification of leukemia, lymphoma and plasma cell dyscrasia when there is only a small amount of specimen (3 to 6-color flow cytometry may yield incomplete information) Aid to the diagnosis of myelodysplastic syndromes and chronic myeloproliferative neoplasms Lymphoma staging (e.g., blood, bone marrow, and occasionally cerebrospinal fluid) Monitoring of residual or relapsed disease after therapy Identification of prognostic markers or therapeutic targets Use of Polymerase Chain Reaction (PCR) Histologic and immunophenotypic methods have been essential in diagnosing B cell and T cell neoplasms in paraffin-embedded or fresh tissue, by identifying cell lineage and confirming aberrant antigen expression. In some B cell lymphomas, particularly those showing plasma cell differentiation, clonality can be demonstrated by IHC via restricted immunoglobulin light chain expression. However, for all T cell neoplasms and many B cell neoplasms in paraffin-embedded or fresh tissues, clonality determination is not currently possible by IHC, and therefore may require molecular studies. Assays that detect monoclonal rearrangement of B cell immunoglobulin heavy chain (IgH) or kappa light chain (IgK) genes, and T cell receptor gamma chain (TCR-gamma) genes, are essential in the evaluation for B and T cell lymphomas, respectively. This is especially true when only formalin-fixed, paraffin-embedded material is available, or when the lymphoid population is atypical but lacks definitive histologic and/or immunophenotypic features of lymphoma. These molecular studies are particularly helpful in the diagnosis of lymphomas in small biopsies involving extranodal sites, such as the gastrointestinal tract or skin, and can often be applied successfully to decalcified material containing atypical lymphoid infiltrates. Polymerase chain reaction (PCR) technology, optimized for use in formalin-fixed, paraffin-embedded tissue, has become a rapid, sensitive, and specific way to detect clonality in atypical lymphoid proliferations. Importantly, interpretation of molecular studies in the context of the histologic features, IHC findings, and clinical history is required to establish a definitive diagnosis in atypical lymphoid proliferations. At PhenoPath, our validated gene rearrangement assays target the IgH, IgK, and TCR-gamma genes, and use methodology based on the landmark European Biomed-2 consortium recommendations. All gene rearrangement PCR assays are performed in duplicate, to minimize the possibility of false-positives. Diagnosing myeloproliferative neoplasms: The great majority of myeloproliferative neoplasms are defined by one of two different molecular abnormalities: 1) the t(9;22)(q34;q11.2), which produces the BCR-ABL fusion gene that gives rise to chronic myelogenous leukemia (CML); and 2) the JAK2 gene V617F mutation, which is described in >90% of polycythemia vera cases, and 50-60% of cases of essential thrombocytosis and primary myelofibrosis. PhenoPath offers PCR-based assays to detect both of these molecular abnormalities. The BCR-ABL assay is a quantitative reverse transcription PCR (RT-PCR) assay with sensitivity down to 1 in 100,000 cells. The JAK2 V617F assay is a real-time, DNA-based PCR assay with sensitivity down to 1% involvement. Both assays can be performed on fresh specimens of any type. For the quantitative BCR-ABL assay, which is the gold standard for monitoring response to therapy in CML, our reports include both current and previous results (performed at PhenoPath), to document trends in the patient s disease
2 HEMATOPATHOLOGY DIAGNOSIS & SUBTYPING HEMATOPATHOLOGY DIAGNOSIS & SUBTYPING Use of Fluorescence In Situ Hybridization (FISH) FISH studies to confirm chromosomal translocations or gene rearrangements: Leukemias, lymphomas, and plasma cell dyscrasias frequently bear specific chromosomal abnormalities that can be detected with high sensitivity and specificity by fluorescence in situ hybridization (FISH). Identification of these translocations can provide crucial confirmatory diagnostic information in problematic cases, and can also help to guide therapy. For example, the identification of a t(15;17) in an AML patient confirms the diagnosis of acute promyelocytic leukemia (AML-M3 under the French-American-British classification system), and suggests that this patient will benefit from the therapeutic use of all-trans-retinoic acid, in addition to cytotoxic chemotherapy. Similarly, the identification of a chromosomal rearrangement involving the c-myc gene confirms the diagnosis of Burkitt lymphoma in the appropriate clinical, histologic, and immunophenotypic context, while identifying the t(11;18) in a patient with gastric marginal zone B cell lymphoma (MALT lymphoma) confirms this diagnosis and predicts poor response to Helicobacter pylori eradication antibiotic therapy. Many of the FISH studies performed at PhenoPath are amenable to either fresh cells or formalin-fixed, paraffinembedded tissue sections. PhenoPath s FISH studies appropriate for hematopoietic neoplasms are listed in Table 2 (page 55). Use of Cytogenetic Studies (Standard Karyotyping) PhenoPath offers standard karyotyping for the full range of specimens amenable to this technology, including fresh bone marrow, blood, tissue (including products of conception), and body fluid (including amniotic fluids). If clinically indicated, reflexive FISH studies can be performed on material originally submitted for standard karyotyping. Use of Multimodality Approaches to Hematopathology Diagnoses Distinguishing reactive follicular hyperplasia from follicular lymphoma: Typically, reactive lymphoid follicles contain CD10-positive, bcl-6-positive, germinal center-type B cells that lack bcl-2 expression and have a high Ki-67-defined cell proliferation index with frequent polarization. In follicular lymphoma (FL), the germinal center B cells usually overexpress bcl-2 as a consequence of the t(14;18)(q32;q21), and usually display a lower Ki-67-defined cell proliferation index. The presence of significant numbers of germinal center-type B cells outside of follicles also supports the diagnosis of FL. A minority of cases of t(14;18)(q32;q21)-positive FL lack detectable bcl-2 overexpression using the most common anti-bcl-2 monoclonal antibody (clone 124), but can often be shown to overexpress bcl-2 with a second monoclonal antibody (clone C2) that has been validated for clinical use at PhenoPath. In rare FL cases lacking detectable bcl-2 overexpression with either antibody, FISH will identify the t(14;18)(q32;q21). In other cases, FISH may identify a rearrangement of the bcl-6 gene. bcl-6 bcl-2 clone 124 bcl-2 clone C2 In cases that remain equivocal after both IHC and FISH, immunoglobulin heavy chain or kappa light chain gene PCR studies can be used to document clonal gene rearrangements in order to prove malignancy. Additional markers of germinal center origin that can be evaluated by IHC at PhenoPath include GCET1 and LMO2. Reproducible clonal peak Small biopsy with follicular lymphoma (FL), evaluated with two different bcl-2 antibodies. The first two rows of figures include summary dot-plots of 9-color flow cytometric (FC) evaluation of a small needle core biopsy. The neoplastic B cell population is colored black, and expresses normal/high-level CD45 and CD20, abnormally decreased CD19 (compared to the residual normal B cells colored blue and red in the histograms), lambda-restricted light chains, intermediate CD10, and low-intermediate CD38. FC evaluation with anti-bcl-2 clone 124, the most common diagnostic antibody, shows that the tumor cells do NOT overexpress bcl-2 when compared to the light green-colored T cells or lavender-colored residual benign B cells. IHC on the small amount of paraffin-embedded tissue (see images) shows that the bcl-6+, CD10+ follicle center B cells are bcl-2-negative with clone 124, but uniformly bcl-2+ with alternative anti-bcl-2 clone C2, confirming the diagnosis of FL. The different IHC results likely reflect a mutation in the 14 amino acid clone 124 epitope (the clone C2 epitope is thought to be much longer). We use clone C2 in the IHC workup of any suspected FL that appears bcl-2-negative with clone 124. Note the IgH chain gene PCR (on the same case) using the FR2 primer set (blue, with control DNA ladder shown in red), showing a reproducible clonal peak of ~272 base pairs, amid a few minor, non-reproducible peaks
3
4
5 HEMATOPATHOLOGY DIAGNOSIS & SUBTYPING HEMATOPATHOLOGY DIAGNOSIS & SUBTYPING Anaplastic large cell lymphoma (ALCL), ALK positive, identifiable by both flow cytometry and IHC. The two rows of flow histograms show a cerebrospinal fluid containing a high proportion of abnormal large CD30+ T cells (colored black in these images), consistent with involvement by the patient s known ALK+ ALCL. The neoplastic cells show increased forward scatter (FSC) indicating large cell size, plus high-level coexpression of CD30, CD25, and HLA-DR, and expression of only CD4 among the T cell antigens evaluated (negative for CD2, CD3, CD5, CD7, CD8, and CD56). The lower row of flow histograms shows aberrant tumor cell expression of the myeloid-associated antigen CD13, which is common in ALK+ ALCL. However, the lack of CD64 and CD33 (not shown) argues strongly against this representing a monocytic population. The three photomicrographs are from a different, lymph node-based case of ALK+ ALCL. The bottom left image shows combined nuclear and cytoplasmic ALK expression, suggesting the t(2;5). The central figure shows the characteristic high-level expression of the potential therapeutic target CD25. The bottom right photomicrograph shows cytoplasmic expression of clusterin, an antigen expressed in both systemic and cutaneous ALCLs, and useful in distinguishing these neoplasms from CD30+ peripheral T cell lymphoma, not otherwise specified. Peripheral T cell lymphoma, not otherwise specified (PTCL, NOS), of gamma-delta origin. By flow cytometry, the neoplastic T cells (colored black in the two rows of flow histograms) are a markedly expanded, abnormal gamma-delta population with uniform aberrant loss of CD5 and acquisition of CD56 and CD16. The gamma-delta lineage of these cells is confirmed by IHC on the paraffin-embedded tissue, which shows that the CD3+ tumor cells (bottom left) lack TCR-beta (central image, showing a few residual benign alpha-beta T cells), and uniformly express TCR-gamma (bottom right). Note the TCR-γ chain PCR (in the same case) using Vγ1f-Jγ (green) and Vγ10-Jγ (blue) primer sets (DNA ladder shown in red). Reproducible clonal peak ALK CD25 Clusterin CD3 TCR-ßF1 TCRγ
6
7 H EMATOPATHOLOGY D IAGNOSIS & S UBTYPING H&E CD117 (c-kit) H EMATOPATHOLOGY D IAGNOSIS & S UBTYPING CD71 CD123 HLA-DR TCL1 Blastic plasmacytoid dendritic cell neoplasm. This is a very rare neoplasm of putative plasmacytoid dendritic cell origin. The images are from a single case involving the bone marrow. The two rows of flow histograms show a fairly characteristic immunophenotype, with no significant expression of the lymphoid and/ or myeloid blast-associated antigens CD34 or CD117. Instead, the neoplastic cells express uniform HLA-DR (at lower-than-usual levels in this case), CD123, CD4, and CD56. As in a subset of these cases, the cells in this case express the myeloid-associated antigen CD33, but lack other myeloid antigens including CD13, CD64, and cytoplasmic myeloperoxidase. The photomicrographs, taken from the bone marrow core biopsy, show the characteristic uniform CD123 and the diagnosisdefining expression of TCL1. HLA-DR shows only variable weak positivity on the tumor cells (mature B cells and monocytes are favored to represent the strongly positive cells). E-cadherin Glycophorin A CD33 Myelodysplastic syndrome, unclassifiable (MDS-U), in which IHC on the bone marrow core biopsy is the key to the diagnosis. In this complex case from an elderly male with pancytopenia, 9/10-color flow cytometric evaluation of the bone marrow aspirate showed essentially normal immunophenotypes of the myeloid blasts (colored red in the first row of flow histograms) and maturing granulocytes and monocytes (colored dark green and lavender, respectively, in the second row of flow histograms). While flow evaluation of the myeloid cells did not help render a diagnosis, the combined cytogenetic detection of a complex abnormal karyotype in the marrow aspirate, plus the morphologic features of the bone marrow core biopsy, enabled definitive diagnosis. The H&E-stained core biopsy showed markedly hypercellular marrow replaced by a frankly neoplastic hematolymphoid infiltrate including collections of enlarged, blast-like cells. By IHC, these cells expressed uniform CD117, CD71, and E-cadherin, with variable glycophorin A, and no CD33, indicating a proerythroblastic proliferation estimated at 30% of the marrow cellularity. In contrast, CD34+ myeloid blasts represented only ~1% of the marrow cellularity. Because the proportion of erythroid cells did not satisfy criteria for the diagnosis of pure erythroid leukemia, the overall findings were most consisent with MDS-U
8 HEMATOPATHOLOGY DIAGNOSIS & SUBTYPING HEMATOPATHOLOGY DIAGNOSIS & SUBTYPING Table 1: Hematolymphoid neoplasms identified by IHC and flow cytometry at PhenoPath Laboratories Table 2: FISH studies for hematopoietic neoplasms performed at PhenoPath Laboratories TUMOR B cell non-hodgkin lymphoma (generic B-NHL) Chronic lymphocytic leukemia/ small lymphocytic lymphoma Mantle cell lymphoma B cell NHL with plasmacytoid differentiation Follicular lymphoma Hairy cell leukemia Diffuse large B cell lymphoma Burkitt lymphoma T cell non-hodgkin lymphoma Angioimmunoblastic T cell lymphoma Anaplastic large cell lymphoma (systemic) NK/T cell lymphoma, nasal type Plasma cell neoplasms Precursor B lymphoblastic lymphoma/leukemia Precursor T lymphoblastic lymphoma/leukemia Acute myeloid leukemia / granulocytic sarcoma Blastic plasmacytoid dendritic cell tumor Paroxysmal nocturnal hemoglobinuria (PNH) Langerhans cell histiocytosis ANTIGENS EVALUATED BY FLOW AND/OR IHC (in addition to the proliferation marker Ki-67, which is evaluated in most cases) Pan-B cell antigens (CD19, CD20, CD22, CD79a, PAX-5, Oct-2, Bob-1, HLA-DR, CD45, kappa, lambda) Pan-B cell antigens, CD5, CD43, CD23, cyclin D1, CD200, CD79b, CD38, ZAP-70, FMC7, LEF-1 Pan-B cell antigens, CD5, CD43, CD23, cyclin D1, CD200, CD79b, CD38, ZAP-70, FMC7 Pan-B cell antigens, CD138, kappa/lambda light chains, CD5, CD10, CD11c, CD25 Pan-B cell antigens, CD10, CD38, bcl-6, bcl-2; CD21+ follicular dendritic cell (FDC) networks Pan-B cell antigens, CD103, CD11c, CD25, CD123, CD10, cyclin D1, DBA.44, TRAcP Pan-B cell antigens, CD10, bcl-6, MUM-1, GCET1, FOXP1, LMO2, p53, EBER1 mrna Pan-B cell antigens, CD10, bcl-6, bcl-2, CD43, c-myc, EBER1 RNA T cell-associated antigens (CD2, CD3, CD4, CD5, CD7, CD8, CD43, CD45, CD56, TCR-β, TCR-γ) (TCR-β isoforms evaluated by flow only) T cell-associated antigens, CD10, bcl-6, PD-1; expanded CD21+ FDC networks; EBV+ B cells (EBER-1 RNA) T cell-associated antigens, CD30, ALK, TIA-1, EMA, clusterin, CD25 T cell-associated antigens, TIA-1, EBER1 RNA CD138, CD79a, kappa/lambda light chains; CD20, CD56, CD117, CD45, cyclin D1 Pan B cell antigens, TdT, CD10, CD34, aberrant myeloid antigens (CD13, CD15, CD33), CD45 T cell-associated antigens, TdT, CD10, CD34, CD1a, CD99, aberrant myeloid antigens, CD45 Myeloid-associated antigens (CD45, CD11b, CD15, CD33, CD34, CD117, CD38, CD71, CD19, CD43, MPO, CD68, lysozyme, HLA-DR, CD36, CD64, CD13, CD14, CD123, CD16); Erythroidassociated antigens (hemoglobin A, glycophorin A, E-cadherin, CD36, CD71); Megakaryocyteassociated antigens (vwf, CD9, CD36, CD41, CD42b, CD61) Myeloid-associated antigens, CD43, CD4, CD56, CD123, HLA-DR, TCL1, TdT CD59 (erythrocytes), CD14 (monocytes), CD16, CD24, CD66b (neutrophils), FLAER (monos. and neuts.), plus CD45, CD33, HLA-DR, CD10, and CD235a as gating antigens S100, CD1a, CD68, CD43, langerin B-LYMPHOID NEOPLASMS Chromosomal Abnormality Genes Involved Diagnosis t(14;18)(q32;q21) IGH / bcl-2 Follicular lymphoma, DLBCL t(11;14), t(4;14), t(14;16), deletions of 13q14, 13q34, 17p13, and hyperploidy CCND1/IGH, FGFR3/MMSET/IGH, IGH/CMAF, D135319, LAMP1, p53 Plasma cell myeloma t(11;14)(q13;q32) CCND1 / IGH Mantle cell lymphoma t(11;18)(q21;q21) API2 / MALT1 Marginal zone B cell lymphoma t(14;18)(q32;q21) IGH / MALT1 Marginal zone B cell lymphoma t(8;14), t(2;8), t(8;22) c-myc / IGH, IgKappa, IgLambda Burkitt lymphoma, some DLBCL Deletions of 11q22, 13q14, 13q34, 17p13; Trisomy 12 ATM, D13S319, LAMP1, P53 CLL/SLL t(3;14)(q27;q32) bcl-6 Follicular lymphoma, DLBCL t(9;22)(q34;q11.2) BCR/ABL ph+ B-ALL MYELOID NEOPLASMS Chromosomal Abnormality Genes Involved Diagnosis t(9;22)(q34;q11.2) BCR/ABL CML t(8;21)(q22;q22) t(15;17)(q22;q12) 11q23 alterations: t(4;11)(q21;q23), t(9;11)(p22;q23), t(11;19)(q23;p13) AML1 / ETO (RUNX1 / RUNX1T1) PML / RARA MLL gene alterations Acute myeloid leukemia with recurrent genetic abnormalities (AML-M2 under FAB classification) Acute myeloid leukemia with recurrent genetic abnormalities (AML-M3 under FAB classification) AML and ALL Inv(16)/t(16;16)(p13;q22) inv16 / t(16;16)(p13;q22) / MYH11 AML, myelomonocytic with eosinophilia 5/del 5q, 7/del 7q, trisomy 8, deletion 20q Many genes involved Myelodysplastic and myeloproliferative neoplasms Table 3: PCR studies for hematopoetic neoplasms performed at PhenoPath Laboratories MYELOID MUTATIONAL/TRANSLOCATION ANALYSIS Mastocytosis Follicular dendritic cell sarcoma Myeloid-associated antigens, tryptase, c-kit/cd117, CD25, CD2 CD21, CD23, CD35, podoplanin (D2-40) JAK2 by Real Time PCR Detects the V617F mutation in the JAK2 gene, which is used in the diagnosis of polycythemia vera (PV), essential thrombocythemia (ET), and idiopathic myelofibrosis (MF). Post-transplant lymphoproliferative disorders/ HIV-associated lymphoma Pan-B cell antigens, EBER1 RNA, EBV LMP or HHV-8 (KSHV) in a minority of cases; kappa/ lambda light chains, CD138 Quantitative BCR-ABL1 Major & Minor Breakpoint Clusters by Real Time PCR Quantitative assay for the BCR-ABL1 major and minor breakpoint cluster region transcripts using international scale (IS) reporting. Classical Hodgkin lymphoma Nodular lymphocyte-predominant Hodgkin lymphoma Small blue round cell tumors (favor non-hematopoietic), by flow cytometry CD30, CD15, PAX-5, CD20, CD3, CD45, MUM1, Oct-2, Bob-1, fascin, EBER1 Pan B cell antigens, bcl-6, EMA, CD10, CD21, IgD CD45, EpCAM (epithelial cell adhesion marker), CD56, CD99, CD90 IGH Chain Gene Rearrangement Studies IGK (Kappa) Gene Rearrangement Studies B CELL (IGH, IGK) AND T CELL (TCR-y) B cell heavy chain clonality assessment B cell light chain clonality assessment (minimizes false-negatives compared to IGH assay alone) Potential therapeutic targets B cell (CD20, CD22, CD52); T cell (CD25, CD30, CD52); myeloid (CD33) TCR- Chain Gene Rearrangement Studies T cell clonality assessment 54 55
Immunopathology of Lymphoma
Immunopathology of Lymphoma Noraidah Masir MBBCh, M.Med (Pathology), D.Phil. Department of Pathology Faculty of Medicine Universiti Kebangsaan Malaysia Lymphoma classification has been challenging to pathologists.
More informationClassification of Hematologic Malignancies. Patricia Aoun MD MPH
Classification of Hematologic Malignancies Patricia Aoun MD MPH Objectives Know the basic principles of the current classification system for hematopoietic and lymphoid malignancies Understand the differences
More informationDifferential diagnosis of hematolymphoid tumors composed of medium-sized cells. Brian Skinnider B.C. Cancer Agency, Vancouver General Hospital
Differential diagnosis of hematolymphoid tumors composed of medium-sized cells Brian Skinnider B.C. Cancer Agency, Vancouver General Hospital Lymphoma classification Lymphoma diagnosis starts with morphologic
More information2010 Hematopoietic and Lymphoid ICD-O Codes - Alphabetical List THIS TABLE REPLACES ALL ICD-O-3 Codes
Acute basophilic leukemia 9870/3 Acute biphenotypic leukemia [OBS] 9805/3 Acute erythroid leukemia 9840/3 Acute megakaryoblastic leukemia 9910/3 Acute monoblastic and monocytic leukemia 9891/3 Acute myeloid
More information2012 Hematopoietic and Lymphoid ICD-O Codes - Numerical List THIS TABLE REPLACES ALL ICD-O-3 Codes
Malignant lymphoma, NOS 9590/3 Non-Hodgkin lymphoma, NOS 9591/3 B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma 9596/3 Primary
More informationThe spectrum of flow cytometry of the bone marrow
The spectrum of flow cytometry of the bone marrow Anna Porwit Lund University Faculty of Medicine Dept. of Clinical Sciences Div. Oncology and Pathology anna.porwit@med.lu.se Disclosure of speaker s interests
More informationBone Marrow. Procedures Blood Film Aspirate, Cell Block Trephine Biopsy, Touch Imprint
Bone Marrow Protocol applies to acute leukemias, myelodysplastic syndromes, myeloproliferative disorders, chronic lymphoproliferative disorders, malignant lymphomas, plasma cell dyscrasias, histiocytic
More informationContents. vii. Preface... Acknowledgments... v xiii
Contents Preface... Acknowledgments... v xiii SECTION I 1. Introduction... 3 Knowledge-Based Diagnosis... 4 Systematic Examination of the Lymph Node... 7 Cell Type Identification... 9 Cell Size and Cellularity...
More informationCombinations of morphology codes of haematological malignancies (HM) referring to the same tumour or to a potential transformation
Major subgroups according to the World Health Organisation (WHO) Classification Myeloproliferative neoplasms (MPN) Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or
More informationPearls and pitfalls in interpretation of lymphoid lesions in needle biopsies
Pearls and pitfalls in interpretation of lymphoid lesions in needle biopsies Megan S. Lim MD PhD University of Pennsylvania October 8, 2018 Objectives To understand how the trend toward less invasive lymph
More informationADx Bone Marrow Report. Patient Information Referring Physician Specimen Information
ADx Bone Marrow Report Patient Information Referring Physician Specimen Information Patient Name: Specimen: Bone Marrow Site: Left iliac Physician: Accession #: ID#: Reported: 08/19/2014 - CHRONIC MYELOGENOUS
More informationHEMATOPATHOLOGY (SHANDS HOSPITAL AT THE UNIVERSITY OF FLORIDA): Rotation Director: Ying Li, M.D., Ph.D., Assistant Professor
HEMATOPATHOLOGY (SHANDS HOSPITAL AT THE UNIVERSITY OF FLORIDA): Rotation Director: Ying Li, M.D., Ph.D., Assistant Professor I. Description of the rotation: During this rotation, the resident will gain
More informationGENETIC MARKERS IN LYMPHOMA a practical overview. P. Heimann Dpt of Medical Genetics Erasme Hospital - Bordet Institute
GENETIC MARKERS IN LYMPHOMA a practical overview P. Heimann Dpt of Medical Genetics Erasme Hospital - Bordet Institute B and T cell monoclonalities Rearrangement of immunoglobin and TCR genes may help
More informationHepatic Lymphoma Diagnosis An Algorithmic Approach
Hepatic Lymphoma Diagnosis An Algorithmic Approach Ryan M. Gill, M.D., Ph.D. University of California, San Francisco PLEASE TURN OFF YOUR CELL PHONES Disclosure of Relevant Financial Relationships USCAP
More informationMethods used to diagnose lymphomas
Institut für Pathologie Institut für Pathologie Methods used to diagnose lymphomas Prof. Dr.Med. Leticia Quintanilla-Fend Molecular techniques NGS histology Cytology AS-PCR Sanger seq. MYC Immunohistochemistry
More informationCost-Effective Strategies in the Workup of Hematologic Neoplasm. Karl S. Theil, Claudiu V. Cotta Cleveland Clinic
Cost-Effective Strategies in the Workup of Hematologic Neoplasm Karl S. Theil, Claudiu V. Cotta Cleveland Clinic In the past 12 months, we have not had a significant financial interest or other relationship
More information7 Omar Abu Reesh. Dr. Ahmad Mansour Dr. Ahmad Mansour
7 Omar Abu Reesh Dr. Ahmad Mansour Dr. Ahmad Mansour -Leukemia: neoplastic leukocytes circulating in the peripheral bloodstream. -Lymphoma: a neoplastic process in the lymph nodes, spleen or other lymphatic
More informationDETERMINATION OF A LYMPHOID PROCESS
Chapter 2 Applications of Touch Preparation Cytology to Intraoperative Consultations: Lymph Nodes and Extranodal Tissues for Evaluation of Hematolymphoid Disorders INTRODUCTION As discussed in Chap. 1,
More informationIntegrated Hematopathology. Morphology and FCI with IHC
Integrated Hematopathology Morphology and FCI with IHC FrontMatter.indd i 9/6/2009 9:30:12 PM FrontMatter.indd ii 9/6/2009 9:30:18 PM Integrated Hematopathology Morphology and FCI with IHC Cherie H Dunphy,
More informationPhenoPath. Diagnoses you can count on B CELL NON-HODGKIN LYMPHOMA
PhenoPath Diagnoses you can count on B CELL NON-HODGKIN LYMPHOMA C urrent diagnosis of B cell non-hodgkin lymphoma (B-NHL) is based on the 2008 WHO Classification of Tumours of Haematopoietic and Lymphoid
More information3/23/2017. Disclosure of Relevant Financial Relationships. Pitfalls in Immunohistochemistry in Hematopathology: CD20 and CD3 Can Let Me Down?!
Pitfalls in Immunohistochemistry in Hematopathology: CD20 and CD3 Can Let Me Down?! Judith A. Ferry Massachusetts General Hospital Disclosure of Relevant Financial Relationships USCAP requires that all
More informationMolecular Pathology of Lymphoma (Part 1) Rex K.H. Au-Yeung Department of Pathology, HKU
Molecular Pathology of Lymphoma (Part 1) Rex K.H. Au-Yeung Department of Pathology, HKU Lecture outline Time 10:00 11:00 11:15 12:10 12:20 13:15 Content Introduction to lymphoma Review of lymphocyte biology
More informationObjectives. Morphology and IHC. Flow and Cyto FISH. Testing for Heme Malignancies 3/20/2013
Molecular Markers in Hematologic Malignancy: Ways to locate the needle in the haystack. Objectives Review the types of testing for hematologic malignancies Understand rationale for molecular testing Marcie
More informationCase year old male with abdominal lymphadenopathy Treated with 8 cycles of R-CHOP One year later B-symptoms and progressive disease
Codirectors Tsieh Sun, M.D., FASCP Francisco Vega, M.D., Ph.D. Department of Hematopathology UT MD Anderson Cancer Center Houston Texas There is no conflict of interest involved in the content and presentation
More informationBeyond the CBC Report: Extended Laboratory Testing in the Evaluation for Hematologic Neoplasia Disclosure
Beyond the CBC Report: Extended Laboratory Testing in the Evaluation for Hematologic Neoplasia Disclosure I am receiving an honorarium from Sysmex for today s presentation. 1 Determining the Etiology for
More informationHEMATOPATHOLOGY SUMMARY REPORT RL;MMR;
HEMATOPATHOLOGY SUMMARY REPORT RL;MMR; Page 1 of 1 05/15/20XX HP000000-20XX 05/21/20XX (212) 123-457 (51) 32-3455 (51) 123-457 Age: 78 DOB: 0/05/19XX SS#: 45-45-45 Clinical Information: 78 y/o female with
More informationCase Report A case of EBV positive diffuse large B-cell lymphoma of the adolescent
Int J Clin Exp Med 2014;7(1):307-311 www.ijcem.com /ISSN:1940-5901/IJCEM1311029 Case Report A case of EBV positive diffuse large B-cell lymphoma of the adolescent Qilin Ao 2, Ying Wang 1, Sanpeng Xu 2,
More informationMixed Phenotype Acute Leukemias
Mixed Phenotype Acute Leukemias CHEN GAO; AMY M. SANDS; JIANLAN SUN NORTH AMERICAN JOURNAL OF MEDICINE AND SCIENCE APR 2012 VOL 5 NO.2 INTRODUCTION Most cases of acute leukemia can be classified based
More informationSmall B-cell (Histologically Low Grade) Lymphoma
Frequency of Lymphoid Neoplasms Small B-cell (Histologically Low Grade) Lymphoma Stephen Hamilton-Dutoit Institute of Pathology Aarhus University Hospital B-cell neoplasms 88% Diffuse large B-cell lymphoma
More informationMany of the hematolymphoid disorders are derived
REVIEW ARTICLE Practical Immunohistochemistry in Hematopathology: A Review of Useful Antibodies for Diagnosis Ji Lu, MD and Karen L. Chang, MD Abstract: This review article offers some useful panels of
More informationCorrigenda. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (revised 4th edition): corrections made in second print run
Corrigenda WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (revised 4th edition): corrections made in second print run In addition to corrections of minor typographical errors, corrections
More informationImmunohistochemical classification of haematolymphoid tumours. Stephen Hamilton-Dutoit Institute of Pathology Aarhus University Hospital
Immunohistochemical classification of haematolymphoid tumours Stephen Hamilton-Dutoit Institute of Pathology Aarhus University Hospital Malignant lymphoproliferative diseases What are they? Haematolymphoid
More informationNon-Hodgkin s Lymphomas Version
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Non-Hodgkin s Lymphomas Version 2.2015 NCCN.org Continue Use of Immunophenotyping/ Genetic Testing in Differential Diagnosis of Mature B-Cell
More informationPathology of Hematopoietic and Lymphoid tissue
CONTENTS Pathology of Hematopoietic and Lymphoid tissue White blood cells and lymph nodes Quantitative disorder of white blood cells Reactive lymphadenopathies Infectious lymphadenitis Tumor metastasis
More informationHeme 9 Myeloid neoplasms
Heme 9 Myeloid neoplasms The minimum number of blasts to diagnose acute myeloid leukemia is 5% 10% 20% 50% 80% AML with the best prognosis is AML with recurrent cytogenetic abnormality AML with myelodysplasia
More informationPathology of Hematopoietic and Lymphoid tissue
Pathology of Hematopoietic and Lymphoid tissue Peerayut Sitthichaiyakul, M.D. Department of Pathology and Forensic Medicine Faculty of Medicine, Naresuan University CONTENTS White blood cells and lymph
More informationFOLLICULARITY in LYMPHOMA
FOLLICULARITY in LYMPHOMA Reactive Follicular Hyperplasia Follicular Hyperplasia irregular follicles Follicular Hyperplasia dark and light zones Light Zone Dark Zone Follicular hyperplasia MIB1 Follicular
More informationFrom Morphology to Molecular Pathology: A Practical Approach for Cytopathologists Part 1-Cytomorphology. Songlin Zhang, MD, PhD LSUHSC-Shreveport
From Morphology to Molecular Pathology: A Practical Approach for Cytopathologists Part 1-Cytomorphology Songlin Zhang, MD, PhD LSUHSC-Shreveport I have no Conflict of Interest. FNA on Lymphoproliferative
More informationPathology. #11 Acute Leukemias. Farah Banyhany. Dr. Sohaib Al- Khatib 23/2/16
35 Pathology #11 Acute Leukemias Farah Banyhany Dr. Sohaib Al- Khatib 23/2/16 1 Salam First of all, this tafreegh is NOT as long as you may think. If you just focus while studying this, everything will
More informationHematopathology Case Study
www.medfusionservices.com Hematopathology Case Study CV3515-14 JUNE Clinical Presentation: Clinical Information: A 42 year old male with history of chronic myelogenous leukemia (CML) presents with an elevated
More informationThe development of clonality testing for lymphomas in the Bristol Genetics Laboratory. Dr Paula Waits Bristol Genetics Laboratory
The development of clonality testing for lymphomas in the Bristol Genetics Laboratory Dr Paula Waits Bristol Genetics Laboratory Introduction The majority of lymphoid malignancies belong to the B cell
More informationCase 3. Ann T. Moriarty,MD
Case 3 Ann T. Moriarty,MD Case 3 59 year old male with asymptomatic cervical lymphadenopathy. These images are from a fine needle biopsy of a left cervical lymph node. Image 1 Papanicolaou Stained smear,100x.
More informationAcute myeloid leukemia. M. Kaźmierczak 2016
Acute myeloid leukemia M. Kaźmierczak 2016 Acute myeloid leukemia Malignant clonal disorder of immature hematopoietic cells characterized by clonal proliferation of abnormal blast cells and impaired production
More informationIntegrated Diagnostic Approach to the Classification of Myeloid Neoplasms. Daniel A. Arber, MD Stanford University
Integrated Diagnostic Approach to the Classification of Myeloid Neoplasms Daniel A. Arber, MD Stanford University What is an integrated approach? What is an integrated approach? Incorporating all diagnostic
More informationChanges to the Hematopoietic and Lymphoid Neoplasm Coding Manual
Changes to the Hematopoietic and Lymphoid Neoplasm Coding Manual KCR 2018 SPRING TRAINING 2018 Hematopoietic Database Updates Updates were done to the Hematopoietic Database based on the WHO Hematopoietic
More informationSuccessful flow cytometric immunophenotyping of body fluid specimens
Successful flow cytometric immunophenotyping of body fluid specimens Fiona E. Craig, MD Division of Hematopathology Mayo Clinic Arizona 2017 MFMER slide-1 Financial disclosure No conflicts 2017 MFMER slide-2
More informationMPL W515L K mutation
MPL W515L K mutation BCR-ABL genotyping The exact chromosomal defect in Philadelphia chromosome is a translocation. Parts of two chromosomes, 9 and 22, switch places. The result is a fusion gene, created
More informationClassification! Immunohistochemical classification of haematolymphoid tumours. Malignant lymphoproliferative diseases
Immunohistochemical classification of haematolymphoid tumours Haematolymphoid Neoplasias: Leukaemia vs Lymphoma C L O N A L M A L I G N A N C I E S Stephen Hamilton-Dutoit Institute of Pathology Aarhus
More informationJAK2 V617F analysis. Indication: monitoring of therapy
JAK2 V617F analysis BCR-ABL genotyping The exact chromosomal defect in Philadelphia chromosome is a translocation. Parts of two chromosomes, 9 and 22, switch places. The result is a fusion gene, created
More informationHematology Unit Lab 2 Review Material
Objectives Hematology Unit Lab 2 Review Material - 2018 Laboratory Instructors: 1. Assist students during lab session Students: 1. Review the introductory material 2. Study the case histories provided
More informationWHO Classification. B-cell chronic lymphocytic leukemia/small T-cell granular lymphocytic leukemia
Blood Malignancies-II Prof. Dr. Herman Hariman, a Ph.D, SpPK (KH). Prof. Dr. Adikoesoema Aman, SpPK (KH) Dept. of Clinical Pathology, School of Medicine, University of North Sumatra WHO classification
More informationAML: WHO classification, biology and prognosis. Dimitri Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen
AML: WHO classification, biology and prognosis Dimitri Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen Acute myeloid leukemia Clonal expansion of undifferentiated myeloid precursors Impaired
More informationHEMATOLOGIC MALIGNANCIES BIOLOGY
HEMATOLOGIC MALIGNANCIES BIOLOGY Failure of terminal differentiation Failure of differentiated cells to undergo apoptosis Failure to control growth Neoplastic stem cell FAILURE OF TERMINAL DIFFERENTIATION
More information2007 Workshop of Society for Hematopathology & European Association for Hematopathology Indianapolis, IN, USA Case # 228
2007 Workshop of Society for Hematopathology & European Association for Hematopathology Indianapolis, IN, USA Case # 228 Vishnu V. B Reddy, MD University of Alabama at Birmingham Birmingham, AL USA 11/03/07
More informationA Practical Guide To Diagnose B-Cell Lymphomas on FNAs. Nancy P. Caraway, M.D.
A Practical Guide To Diagnose B-Cell Lymphomas on FNAs Nancy P. Caraway, M.D. Major Factors Impacting Dx Lymphomas on Small Bxs Classification systems Immunophenotyping by multiprobe flow cytometry and
More information5000 International Clinical Cytometry Society: Practical Flow Cytometry in Hematopathology A Case-Based Approach
5000 International Clinical Cytometry Society: Practical Flow Cytometry in Hematopathology A Case-Based Approach Joseph A DiGiuseppe, MD, PhD Hartford Hospital Disclosures In the past 12 months, I have
More informationMolecular Hematopathology
Molecular Hematopathology Charles E. Hill, MD, PhD Emory University School of Medicine April 2013 The Association for Molecular Pathology Education. Innovation and Improved Patient Care. Advocacy. www.amp.org
More information88-year-old Female with Lymphadenopathy. Faizi Ali, MD
88-year-old Female with Lymphadenopathy Faizi Ali, MD Clinical History A 88-year-old caucasian female presented to our hospital with the complaints of nausea, vomiting,diarrhea, shortness of breath and
More information11/2/2017. Immunodeficiencies. Joo Y. Song, MD Assistant Professor of Clinical Pathology. I have no financial disclosures.
I have no financial disclosures Joo Y. Song, MD Assistant Professor of Clinical Pathology City of Hope National Medical Center Immunodeficiencies Transplant Autoimmunity Drugs T-cell dysfunction (Age,
More informationNon-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL)
Non-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL) Lymphoid Neoplasms: 1- non-hodgkin lymphomas (NHLs) 2- Hodgkin lymphoma 3- plasma cell neoplasms Non-Hodgkin lymphomas (NHLs) Acute Lymphoblastic Leukemia/Lymphoma
More informationHODGKIN LYMPHOMA DR. ALEJANDRA ZARATE OSORNO HOSPITAL ESPAÑOL DE MEXICO
HODGKIN LYMPHOMA DR. ALEJANDRA ZARATE OSORNO HOSPITAL ESPAÑOL DE MEXICO HODGKIN LYMPHOMA CLASSIFICATION Lukes & Butler Rye WHO-2016 Linphocytic and/or histiocytic Nodular & diffuse Nodular Sclerosis Lymphocyte
More information2013 AAIM Pathology Workshop
2013 AAIM Pathology Workshop John Schmieg, M.D., Ph.D. None Disclosures 1 Pathology Workshop Objectives Define the general philosophy of reviewing pathology reports Review the various components of Bone
More informationAcute Myeloid Leukemia with Recurrent Cytogenetic Abnormalities
Acute Myeloid Leukemia with Recurrent Cytogenetic Abnormalities Acute Myeloid Leukemia with recurrent cytogenetic Abnormalities -t(8;21)(q22;q22)(aml/eto) -inv(16) or t(16;16) -t(15;17) -11q23 Acute Myeloid
More informationMyeloproliferative Disorders - D Savage - 9 Jan 2002
Disease Usual phenotype acute leukemia precursor chronic leukemia low grade lymphoma myeloma differentiated Total WBC > 60 leukemoid reaction acute leukemia Blast Pro Myel Meta Band Seg Lymph 0 0 0 2
More informationWBCs Disorders 1. Dr. Nabila Hamdi MD, PhD
WBCs Disorders 1 Dr. Nabila Hamdi MD, PhD ILOs Compare and contrast ALL, AML, CLL, CML in terms of age distribution, cytogenetics, morphology, immunophenotyping, laboratory diagnosis clinical features
More informationAggressive B-cell Lymphoma 2013
Aggressive B-cell Lymphoma 2013 Diffuse Large B-Cell Lymphoma Burkitt Lymphoblastic lymphoma Gray zone Intermediate DLBCL/HL Intermediate BL/DLBCL Diffuse Large B-cell lymphoma Common morphology: diffuse
More informationBurkitt lymphoma. Sporadic Endemic in Africa associated with EBV Translocations involving MYC gene on chromosome 8
Heme 8 Burkitt lymphoma Sporadic Endemic in Africa associated with EBV Translocations involving MYC gene on chromosome 8 Most common is t(8;14) Believed to be the fastest growing tumor in humans!!!! Morphology
More information10/31/2017. Immunodeficiencies. Outline. Discuss EBV. Non-destructive Polymorphic Monomorphic Therapies Challenges
I have no financial disclosures Joo Y. Song, MD Assistant Professor of Clinical Pathology City of Hope National Medical Center Immunodeficiencies Outline Transplant Congenital Autoimmunity T-cell/immune
More informationDefined lymphoma entities in the current WHO classification
Defined lymphoma entities in the current WHO classification Luca Mazzucchelli Istituto cantonale di patologia, Locarno Bellinzona, January 29-31, 2016 Evolution of lymphoma classification Rappaport Lukes
More informationV. Acute leukemia. Flow cytometry in evaluation of hematopoietic neoplasms: A case-based approach
V. Acute leukemia Evaluating a sample for an acute leukemia Acute leukemia is a neoplasm of immature myeloid or lymphoid cells characterized by a block in maturation, usually at the stage of an early progenitor
More informationLEUKAEMIA and LYMPHOMA. Dr Mubarak Abdelrahman Assistant Professor Jazan University
LEUKAEMIA and LYMPHOMA Dr Mubarak Abdelrahman Assistant Professor Jazan University OBJECTIVES Identify etiology and epidemiology for leukemia and lymphoma. Discuss common types of leukemia. Distinguish
More informationHematology Diagnostic Services
Cleveland Clinic Laboratories Hematology Diagnostic Services Trust in us for everything you need in a reference lab. Our Mission The Pathology and Laboratory Medicine Institute contributes to excellent
More informationSession 5. Pre-malignant clonal hematopoietic proliferations. Chairs: Frank Kuo and Valentina Nardi
Session 5 Pre-malignant clonal hematopoietic proliferations Chairs: Frank Kuo and Valentina Nardi Pre-malignant clonal hematopoietic proliferations Clonal LYMPHOID proliferations: - Monoclonal gammopathy
More informationHEMATOPATHOLOGY SERVICES
HEMATOPATHOLOGY SERVICES Know what your patient s future holds, NOW. Driven by patient care, GoPath Laboratories has set a new standard for hematologic cancer testing. thick, 2 slides per probe minimum
More informationMimics of Lymphoma in Routine Biopsies. I have nothing to disclose regarding the information to be reported in this talk.
Mimics of Lymphoma in Routine Biopsies Patrick Treseler, MD, PhD Professor of Pathology University of California San Francisco I have nothing to disclose regarding the information to be reported in this
More informationImmunophenotyping of lymphoproliferative disorders: state of the art
Pathology (December 2005) 37(6), pp. 457 478 PRACTICAL ASPECTS OF DIAGNOSTIC HISTOPATHOLOGY Immunophenotyping of lymphoproliferative disorders: state of the art EMMA J. GUDGIN AND WENDY N. ERBER Haematology
More information11/8/2018 DISCLOSURES. I have NO Conflicts of Interest to Disclose. UTILTY OF DETECTING PATTERNS
Bharat N. Nathwani, M.D. City of Hope Medical Center Professor, Director of Pathology Consultation Services, 1500 East Duarte Road, Duarte, California, 91010 DISCLOSURES -------------------------------------------------------
More informationMolecular Diagnosis. Nucleic acid based testing in Oncology
Molecular Diagnosis Nucleic acid based testing in Oncology Objectives Describe uses of NAT in Oncology Diagnosis, Prediction, monitoring. Genetics Screening, presymptomatic testing, diagnostic testing,
More informationInitial Diagnostic Workup of Acute Leukemia
Initial Diagnostic Workup of Acute Leukemia Guideline from the College of American Pathologists (CAP) and the American Society of Hematology (ASH) Publication: Archives of Pathology and Laboratory Medicine
More informationNucleic Acid Testing - Oncology. Molecular Diagnosis. Gain/Loss of Nucleic Acid. Objectives. MYCN and Neuroblastoma. Molecular Diagnosis
Nucleic Acid Testing - Oncology Molecular Diagnosis Nucleic acid based testing in Oncology Gross alterations in DNA content of tumors (ploidy) Gain/Loss of nucleic acids Markers of Clonality Oncogene/Tumor
More informationLymphoma: What You Need to Know. Richard van der Jagt MD, FRCPC
Lymphoma: What You Need to Know Richard van der Jagt MD, FRCPC Overview Concepts, classification, biology Epidemiology Clinical presentation Diagnosis Staging Three important types of lymphoma Conceptualizing
More informationDiagnostic Approach for Eosinophilia and Mastocytosis. Curtis A. Hanson, M.D.
Diagnostic Approach for Eosinophilia and Mastocytosis Curtis A. Hanson, M.D. 2014 MFMER slide-1 DISCLOSURES: Relevant Financial Relationship(s) None Off Label Usage None 2014 MFMER slide-2 Molecular Classification
More informationExtramedullary precursor T-lymphoblastic transformation of CML at presentation
Extramedullary precursor T-lymphoblastic transformation of CML at presentation Neerja Vajpayee, Constance Stein, Bernard Poeisz & Robert E. Hutchison Clinical History 30 year old man presented to the emergency
More information5003 Immunohistochemistry in hematopathology, what's in, what's out, what's useful
www.ascp.org/ascp2014 5003 Immunohistochemistry in hematopathology, what's in, what's out, what's useful Kathryn Rizzo, DO, PhD VIRGINIA COMMONWEALTH UNIVERSITY Department of Pathology School of Medicine
More informationT cell lymphoma diagnostics and differential diagnosis to Hodgkin lymphoma
T cell lymphoma diagnostics and differential diagnosis to Hodgkin lymphoma Sylvia Hartmann Dr. Senckenberg Institute of Pathology Goethe University Frankfurt Overview Borderline ALCL classical HL Borderline
More informationIntroduction: The Revised (4 th Edition) World Health Organization (WHO) Classification of Tumors of Hematopoietic and Lymphoid Tissues
Society for Hematopathology Scientific Symposium USCAP Companion Meeting, Boston, MA March 8, 2009 Boston, MA Steven H. Swerdlow and James Vardiman, Moderators Introduction: The Revised (4 th Edition)
More informationApproach to Core Biopsy Specimens
BDIAP 108th Symposium on Haematopathology Joint Meeting of the BDIAP and BLPG at-bristol, Anchor Road, Harbourside, Bristol BS1 5DB 15th - 17th May 2014 Approach to Core Biopsy Specimens Dr Stefan Dojcinov
More informationLYMPHOMAS an overview of some subtypes of NHLs
One of the confusing aspects of the lymphoid neoplasms concerns the use of the descriptive terms "leukemia" and "lymphoma." LYMPHOMAS an overview of some subtypes of NHLs Leukemia is used for lymphoid
More informationTest Name Results Units Bio. Ref. Interval. Positive
LL - LL-ROHINI (NATIONAL REFERENCE 135091533 Age 28 Years Gender Male 1/9/2017 120000AM 1/9/2017 105415AM 4/9/2017 23858M Ref By Final LEUKEMIA DIAGNOSTIC COMREHENSIVE ROFILE, ANY 6 MARKERS t (1;19) (q23
More informationHematology Page 1 of 8
Hematology Page 1 of 8 Hematology Major Category Code Headings Revised 12/17 1 Basic methodology and test armamentarium 20000 2 Normal hematopoiesis & hemostasis 20100 3 RBC disorders, non-neoplastic 20340
More informationFLOW CYTOMETRY PRINCIPLES AND PRACTICE. Toby Eyre Consultant Haematologist Oxford University Hospitals NHS Foundation Trust June 2018
FLOW CYTOMETRY PRINCIPLES AND PRACTICE Toby Eyre Consultant Haematologist Oxford University Hospitals NHS Foundation Trust June 2018 Aims and Objectives Principles of flow cytometry Preparation Steps involved
More informationMyeloid neoplasms. Early arrest in the blast cell or immature cell "we call it acute leukemia" Myoid neoplasm divided in to 3 major categories:
Myeloid neoplasms Note: Early arrest in the blast cell or immature cell "we call it acute leukemia" Myoid neoplasm divided in to 3 major categories: 1. AML : Acute myeloid leukemia(stem cell with myeloid
More informationProtocol for the Examination of Specimens From Patients With Hematopoietic Neoplasms Involving the Bone Marrow*
Protocol for the Examination of Specimens From Patients With Hematopoietic Neoplasms Involving the Bone Marrow* Version: Protocol Posting Date: January 2018 This protocol is NOT required for accreditation
More informationReporting cytogenetics Can it make sense? Daniel Weisdorf MD University of Minnesota
Reporting cytogenetics Can it make sense? Daniel Weisdorf MD University of Minnesota Reporting cytogenetics What is it? Terminology Clinical value What details are important Diagnostic Tools for Leukemia
More informationLarge cell immunoblastic Diffuse histiocytic (DHL) Lymphoblastic lymphoma Diffuse lymphoblastic Small non cleaved cell Burkitt s Non- Burkitt s
Non Hodgkin s Lymphoma Introduction 6th most common cause of cancer death in United States. Increasing in incidence and mortality. Since 1970, the incidence of has almost doubled. Overview The types of
More informationHematolymphoid lesions of the skin Part II Myeloid neoplastic proliferations Houston Society of Clinical Pathologists Symposium April 14, 2018
Hematolymphoid lesions of the skin Part II Myeloid neoplastic proliferations Houston Society of Clinical Pathologists Symposium April 14, 2018 Carlos A. Torres-Cabala, MD Associate Professor Chief, Dermatopathology
More information